The hypothalamus–pituitary–adrenal (HPA) axis appears to be crucial in the development of the symptoms of depression.1 Patients with depression frequently have high circulating levels of cortisol,5 the hormone released from the adrenal cortex.4 Providing evidence for the connection from the other direction, patients with Cushing’s syndrome (characterised by a long-term increase in the levels of glucocorticoids, including cortisol)6 often show symptoms of depression, symptoms which are relieved when the cortisol overactivity is treated.5

Long term HPA overactivity has neurotoxic effects, particularly on the hippocampus.2 One proposed mechanism for the neurotoxic effects of cortisol is via the molecule BDNF (brain-derived neurotrophic factor), which normally sustains the viability of neurones.2,4 Chronic elevated cortisol reduces BDNF levels, which can lead to loss of neurones in the brain, particularly the hippocampus.2,3,4 Interestingly, treatment with antidepressants appears to restore the monoamine depletion seen as a result of chronic stress; this restoration can increase BDNF levels (and other trophic factors) and, potentially, restore some of the changes to the brain seen in depression.3,4

file_download Download in HQ

Related content

Abstract illustration of a human head silhouette formed by layered curved structures with a ladder running through the centre description Article
Treatment-Resistant Depression (TRD) – definition, clinical manifestation, and evidence-based treatment

Major Depressive Disorder (MDD) is a highly prevalent psychiatric condition with significant individual and socio-economic burden​. Despite the broad availability of numerous effective therapeutic interventions, up to 30% of patients fail to achieve adequate symptom relief and are classified as having treatment-resistant depression (TRD). TRD represents a significant clinical challenge, affecting approximately 30% of individuals with MDD who fail to respond to at least two adequate antidepressant trials.

25.09.2025 Depression
image Image Figure showing sequential treatment strategies for improving outcomes in major depressive disorder
Sequental Treatment Optimization Scheme for Major Depressive Disorder

Sequential treatment optimization scheme for major depressive disorder generated according to international evidence.

18.09.2025 Depression
image Image Image showing factors to evaluate when antidepressant treatment response is inadequate
Identification and effective management of factors potentially confounding treatment response

Key steps for managing factors that may confound antidepressant treatment response, including dose, side effects, comorbidities, stressors, adherence, pharmacogenomics, interactions, and treatment algorithms.

18.09.2025 Depression